WallStreetZenWallStreetZen

NASDAQ: RSLS
Reshape Lifesciences Inc Stock

$0.17+0.01 (+6.25%)
Updated Apr 18, 2024
RSLS Price
$0.17
Fair Value Price
$1.58
Market Cap
$4.01M
52 Week Low
$0.14
52 Week High
$2.99
P/E
-0.09x
P/B
0.6x
P/S
0.17x
PEG
N/A
Dividend Yield
N/A
Revenue
$8.68M
Earnings
-$11.39M
Gross Margin
63.9%
Operating Margin
-130.92%
Profit Margin
-131.2%
Debt to Equity
0.6
Operating Cash Flow
-$17M
Beta
1.16
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A

RSLS Overview

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

Zen Score

–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RSLS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RSLS ($0.17) is undervalued by 89.17% relative to our estimate of its Fair Value price of $1.58 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
RSLS ($0.17) is significantly undervalued by 89.17% relative to our estimate of its Fair Value price of $1.58 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
RSLS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RSLS due diligence checks available for Premium users.

Be the first to know about important RSLS news, forecast changes, insider trades & much more!

RSLS News

Valuation

RSLS fair value

Fair Value of RSLS stock based on Discounted Cash Flow (DCF)
Price
$0.17
Fair Value
$1.58
Undervalued by
89.23%
RSLS ($0.17) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RSLS ($0.17) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RSLS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

RSLS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.09x
Industry
28.61x
Market
41.33x

RSLS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.6x
Industry
3.63x
RSLS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

RSLS's financial health

Profit margin

Revenue
$2.0M
Net Income
-$1.7M
Profit Margin
-85.7%
RSLS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RSLS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$10.7M
Liabilities
$4.0M
Debt to equity
0.6
RSLS's short-term assets ($10.30M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RSLS's short-term assets ($10.30M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RSLS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RSLS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.5M
Investing
$0.0
Financing
$5.5M
RSLS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

RSLS vs Medical Device Stocks

TickerMarket Cap1d %P/EP/B
RSLS$4.01M+4.27%-0.09x0.60x
XLYO$4.05M+3.81%-0.28x0.13x
INVO$4.17M-16.48%-0.30x4.67x
AEMD$3.71M-0.35%-0.28x0.49x
VTAK$3.64M+8.58%-0.04x0.17x

Reshape Lifesciences Stock FAQ

What is Reshape Lifesciences's quote symbol?

(NASDAQ: RSLS) Reshape Lifesciences trades on the NASDAQ under the ticker symbol RSLS. Reshape Lifesciences stock quotes can also be displayed as NASDAQ: RSLS.

If you're new to stock investing, here's how to buy Reshape Lifesciences stock.

What is the 52 week high and low for Reshape Lifesciences (NASDAQ: RSLS)?

(NASDAQ: RSLS) Reshape Lifesciences's 52-week high was $2.99, and its 52-week low was $0.14. It is currently -94.28% from its 52-week high and 21.28% from its 52-week low.

How much is Reshape Lifesciences stock worth today?

(NASDAQ: RSLS) Reshape Lifesciences currently has 23,457,090 outstanding shares. With Reshape Lifesciences stock trading at $0.17 per share, the total value of Reshape Lifesciences stock (market capitalization) is $4.01M.

Reshape Lifesciences stock was originally listed at a price of $22,500.02 in Oct 6, 2016. If you had invested in Reshape Lifesciences stock at $22,500.02, your return over the last 7 years would have been -100%, for an annualized return of -81.44% (not including any dividends or dividend reinvestments).

How much is Reshape Lifesciences's stock price per share?

(NASDAQ: RSLS) Reshape Lifesciences stock price per share is $0.17 today (as of Apr 18, 2024).

What is Reshape Lifesciences's Market Cap?

(NASDAQ: RSLS) Reshape Lifesciences's market cap is $4.01M, as of Apr 19, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Reshape Lifesciences's market cap is calculated by multiplying RSLS's current stock price of $0.17 by RSLS's total outstanding shares of 23,457,090.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.